The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA 27.
Steven E. Vogl
No relevant relationships to disclose
Abdullah Khalaf Altwairgi
No relevant relationships to disclose
Judy-Anne W. Chapman
No relevant relationships to disclose
Liting Zhu
No relevant relationships to disclose
Lois E. Shepherd
No relevant relationships to disclose
Paul Edward Goss
Honoraria - Novartis; Pfizer